Peregrine Capital Management LLC Makes New $7.84 Million Investment in Xenon Pharmaceuticals Inc. $XENE

Peregrine Capital Management LLC acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 174,851 shares of the biopharmaceutical company’s stock, valued at approximately $7,837,000.

Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. grew its holdings in shares of Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 717 shares during the last quarter. Danske Bank A S purchased a new position in shares of Xenon Pharmaceuticals during the third quarter worth about $32,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Xenon Pharmaceuticals during the third quarter worth about $39,000. State of Wyoming grew its holdings in shares of Xenon Pharmaceuticals by 112.8% during the third quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 610 shares during the last quarter. Finally, Osaic Holdings Inc. grew its holdings in shares of Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,034 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insider Activity at Xenon Pharmaceuticals

In other news, insider Christopher John Kenney sold 1,410 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $55.23, for a total transaction of $77,874.30. Following the completion of the sale, the insider directly owned 7,069 shares in the company, valued at approximately $390,420.87. This trade represents a 16.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ian Mortimer sold 7,308 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $55.23, for a total transaction of $403,620.84. Following the sale, the chief executive officer owned 19,923 shares of the company’s stock, valued at approximately $1,100,347.29. The trade was a 26.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 296,707 shares of company stock worth $17,845,365 over the last 90 days. Company insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Stock Down 2.2%

Shares of NASDAQ:XENE opened at $55.41 on Friday. The company has a market cap of $4.61 billion, a P/E ratio of -12.71 and a beta of 0.74. Xenon Pharmaceuticals Inc. has a 52 week low of $28.19 and a 52 week high of $63.95. The company has a 50-day moving average price of $52.47 and a 200 day moving average price of $45.67.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter in the previous year, the business posted ($0.84) EPS. Analysts expect that Xenon Pharmaceuticals Inc. will post -4.83 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on XENE shares. Robert W. Baird raised their price objective on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, March 9th. Deutsche Bank Aktiengesellschaft raised their price objective on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Jefferies Financial Group set a $100.00 price objective on Xenon Pharmaceuticals in a report on Monday, March 9th. HC Wainwright raised their price objective on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Finally, Morgan Stanley set a $97.00 price objective on Xenon Pharmaceuticals in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Xenon Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $73.13.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.